Always Cutting-Edge
Working in partnership with Boehringer Ingelheim provides access to a state-of-the-art biopharmaceutical environment. Specific franchise technologies for either microbial or mammalian processes have been established and are very competitive assets of Boehringer Ingelheim's biopharmaceutical business. Continuous process improvements within these technologies do ensure low Cost of Goods in safe, reliable and robust processes operated on a science based approach.
We have the technology
-
Mammalian Cell CultureAt the Boehringer Ingelheim facility in Biberach, Germany, we develop and manufacture recombinant DNA-derived proteins and monoclonal antibodies in mammalian cell culture.
read more
-
Cell Culture TechnologyThe Boehringer Ingelheim BI HEX® is an established high expression platform technology which enables fast-track development of high-quality, high-titer processes.
read more
-
Microbial FermentationBoehringer Ingelheim Austria GmbH pioneered the microbial fermentation and purification of therapeutic proteins from E.coli since 1982.
read more
-
Microbial Fermentation TechnologiesThe broad spectrum of microbial and yeast hosts allows the selection of the best suitable production system in terms of economy, product quality and efficiency.
read more
-
Formulation & Pharma Process DevelopmentBoehringer Ingelheim offers sophisticated pre-formulation, formulation and pharmaceutical process development.
read more
-
Fill & FinishWe offer therapeutic proteins and non-viral vector systems as vial, ampoule or syringe filling and pulmonary application.
read more
-
Quality Control & AssuranceEffective quality control in compliance with cGMP guidelines and the most advanced analytical tools are applied to ensure the concept of "well characterized biopharmaceuticals".
read more
